Medicare膀胱癌患者新辅助化疗完成率及影响因素:SEER-Medicare分析
该研究利用SEER-Medicare数据,纳入2008-2013年间接受膀胱切除术并在术前6个月内接受化疗的594例肌层浸润性膀胱癌患者,其中174例(29%)未完成新辅助化疗。完成者与未完成者的中位化疗时长分别为10.0周和4.4周,年龄和地理区域与未完成独立相关。
要点
- 近30%接受新辅助化疗的膀胱癌患者未完成方案。
- 高龄和地理区域差异是未完成化疗的独立影响因素。
- 顺铂方案与非顺铂方案未完成率分别为27%和33%。
核心结论
- 近30%接受新辅助化疗的肌层浸润性膀胱癌患者未完成方案,高龄和非临床因素(如地理区域实践模式)可能影响完成率。
研究设计与样本
- 基于SEER-Medicare数据的回顾性队列研究,纳入2008-2013年接受膀胱切除术并在术前180天内接受化疗的594例患者。
主要发现
- 174/594例(29%)未完成新辅助化疗。
- 完成者和未完成者的中位化疗时长分别为10.0周(IQR 7.7-11.2)和4.4周(IQR 3.0-8.0)。
- 391例(66%)接受顺铂为基础方案,203例(34%)接受替代方案,未完成率分别为27%和33%。
- 调整协变量后,年龄和地理区域与未完成化疗独立相关。
关键数值与推荐
- 新辅助化疗定义为膀胱切除术前180天内存在化疗报销记录。
- 未完成判定采用基于临床试验和国家指南的方案特异性切点。
临床怎么用
- 临床应关注高龄患者及不同地理区域实践模式对新辅助化疗完成率的影响,针对性优化管理以提高完成率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the rate and determinants of neoadjuvant chemotherapy noncompletion in patients with muscle-invasive bladder cancer. METHODS: Using Surveillance, Epidemiology, and End Results-Medicare data, we identified all patients who underwent cystectomy between 2008-2013 and received chemotherapy within 6 months. Of these, 594 patients received neoadjuvant chemotherapy, defined as the presence of a claim for chemotherapy within the 180 days preceding cystectomy. Our primary outcome was noncompletion of neoadjuvant chemotherapy. We determined regimen-specific cut points for noncompletion based on clinical trials and national guidelines. RESULTS: Over the study period, 174 of 594 patients (29%) did not complete neoadjuvant chemotherapy. Noncompleters and completers received a median interquartile range of 4.4 (3.0-8.0) and 10.0 (7.7-11.2) weeks of chemotherapy, respectively. A total of 391 (66%) patients received a cisplatin-based regimen and 203 (34%) patients received an alternative regimen, with 27% and 33% not completing chemotherapy, respectively. After adjusting for covariates, age and geographic region were independently associated with failing to complete chemotherapy. CONCLUSION: Nearly 30% of patients who received neoadjuvant chemotherapy did not complete their regimen. Advanced age and nonclinical factors, such as practice patterns in certain geographic regions, may influence a patient's likelihood of successfully completing chemotherapy.
引用
- Hugar LA, Yabes JG, Turner RM, et al. Rate and Determinants of Completing Neoadjuvant Chemotherapy in Medicare Beneficiaries With Bladder Cancer: A SEER-Medicare Analysis. Urology. 2018. PMID: 30423302. doi:10.1016/j.urology.2018.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。